Xeris Biopharma: Time For A Pause
The Seeking Alpha article reports that Xeris Biopharma shares more than doubled since the author’s March buy rating, following strong Q3 results and raised guidance. XERS reported GAAP earnings of $0.06 per share, $11.3 million in net income, 44% revenue growth to $107.2 million, 88% gross margins, and repayment of $34 million in convertible notes.
Why it matters — These reported results, higher guidance, and reduced debt and interest costs are relevant indicators of Xeris’s recent operating performance and balance-sheet position.